A 60% reduction in the risk of death — HR 0.40 — in previously treated metastatic pancreatic cancer is a number that stops a room.
For context, second-line PDAC trials have spent two decades grinding toward hazard ratios in the 0.67–0.75 range against chemotherapy, and none has ever pushed median overall survival past a year in any phase 3 setting.
RASolute 302 enrolled 500 patients and prespecified dual primary populations — a RAS G12 mutant cohort and a broader intent-to-treat population that included patients without an identified RAS mutation.
The 33.2% objective response rate in the G12 population, against 11.8% for chemotherapy, reinforces that this is a drug producing genuine tumor regression, not just disease stabilization.
That quality-of-life separation in a population with median OS under seven months on the control arm carries real clinical weight.
A 60% reduction in the risk of death — HR 0.40 — in previously treated metastatic pancreatic cancer is a number that stops a room. For context, second-line PDAC trials have spent two decades grinding toward hazard ratios in the 0.67–0.75 range against chemotherapy, and none has ever pushed median overall survival past a year in any phase 3 setting. Revolution Medicines’ RASolute 302 did exactly that: 13.2 months median OS for daraxonrasib versus 6.6 months for investigator’s choice chemotherapy, published simultaneously in the New England Journal of Medicine and presented as a plenary at ASCO 2026. That is not incremental progress. That is a category break.
The trial’s design choices matter as much as the headline numbers. RASolute 302 enrolled 500 patients and prespecified dual primary populations — a RAS G12 mutant cohort and a broader intent-to-treat population that included patients without an identified RAS mutation. The hazard ratios were essentially identical across both: 0.40 in each, with PFS HRs of 0.45 and 0.49, respectively. That consistency is critical. It validates daraxonrasib’s mechanism as a RAS(ON) multi-selective inhibitor — one designed to suppress constitutively active RAS signaling regardless of the specific variant driving the tumor. The 33.2% objective response rate in the G12 population, against 11.8% for chemotherapy, reinforces that this is a drug producing genuine tumor regression, not just disease stabilization. An ORR triple that of chemo in a disease this refractory demands attention.
The safety readout is where phase 3 trials in PDAC often quietly collapse. Grade 3 or higher treatment-related adverse events hit 43.6% of patients on daraxonrasib — not trivial — but treatment discontinuation due to toxicity was described as low, and patients on daraxonrasib reported significantly delayed deterioration in cancer-related pain, global health status, and quality of life compared to those on chemotherapy. That quality-of-life separation in a population with median OS under seven months on the control arm carries real clinical weight. Physicians won’t just be choosing an efficacy profile; they’ll be choosing a tolerability trajectory for patients who may have months, not years, ahead of them.
The single variable now defining daraxonrasib’s trajectory is the FDA’s response to an anticipated NDA submission — specifically whether the agency accepts the ITT population as the primary registration basis, which would position this drug for an unselected PDAC second-line label rather than one gated on RAS G12 mutation testing. That label scope determines whether this becomes a niche targeted therapy or the default second-line standard of care overnight.
Source link: https://www.globenewswire.com/news-release/2026/05/31/3303919/0/en/Revolution-Medicines-Announces-ASCO-Plenary-Presentation-Highlighting-Unprecedented-Results-from-Pivotal-Phase-3-RASolute-302-Clinical-Trial-of-Daraxonrasib-in-Previously-Treated-M.html
